Neil Mellor - Easton Pharmaceutica Special Consultant
| EAPH Stock | USD 0.0001 0.00 0.000003% |
Executive
Neil Mellor is Special Consultant of Easton Pharmaceutica since 2014.
| Tenure | 11 years |
| Address | 111 Brockhouse Road, Toronto, ON, Canada |
| Phone | 647-362-5700 |
| Web | https://www.eastonpharma.com |
Easton Pharmaceutica Management Efficiency
The current Return On Tangible Assets is estimated to decrease to -0.08. The Easton Pharmaceutica's current Return On Capital Employed is estimated to increase to -0.02. As of now, Easton Pharmaceutica's Debt To Assets are increasing as compared to previous years. The Easton Pharmaceutica's current Asset Turnover is estimated to increase to 0.13, while Intangible Assets are projected to decrease to under 6 M. Easton Pharmaceutica's management efficiency ratios could be used to measure how well Easton Pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | EXECUTIVE Age | ||
| Itai Kabiljo | INC Research Holdings | N/A | |
| Omri Batzir | INC Research Holdings | N/A | |
| Einat Zehavi | INC Research Holdings | N/A | |
Management Performance
| Return On Equity | -0.0269 | ||||
| Return On Asset | -0.0083 |
Easton Pharmaceutica Leadership Team
Elected by the shareholders, the Easton Pharmaceutica's board of directors comprises two types of representatives: Easton Pharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Easton. The board's role is to monitor Easton Pharmaceutica's management team and ensure that shareholders' interests are well served. Easton Pharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Easton Pharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lilla Albert, Chief Officer | ||
| Neil Mellor, Special Consultant | ||
| Evan Karras, President, CEO | ||
| Elena Milantoni, Director Administration |
Easton Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Easton Pharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0269 | ||||
| Return On Asset | -0.0083 | ||||
| Current Valuation | 2.14 M | ||||
| Shares Outstanding | 1.34 B | ||||
| Price To Earning | (22.00) X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 0.06 X | ||||
| Gross Profit | 201.4 K | ||||
| EBITDA | (188.54 K) | ||||
| Net Income | (188.54 K) |
Currently Active Assets on Macroaxis
When determining whether Easton Pharmaceutica offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Easton Pharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Easton Pharmaceutica Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Easton Pharmaceutica Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Easton Pharmaceutica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Easton Stock please use our How to Invest in Easton Pharmaceutica guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Easton Pharmaceutica. If investors know Easton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Easton Pharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Easton Pharmaceutica is measured differently than its book value, which is the value of Easton that is recorded on the company's balance sheet. Investors also form their own opinion of Easton Pharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Easton Pharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Easton Pharmaceutica's market value can be influenced by many factors that don't directly affect Easton Pharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Easton Pharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Easton Pharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Easton Pharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.